Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perception of convenience and preference for the Genotropin Mark VII pen versus current Genotropin Pen
2009-017354-12Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in growth hormone deficiency (GHD) (2 arms), sponsored by Pfizer. Primary endpoint: Ease of use and convenience of Genotropin Mark VII pen. Started Apr 2010; status: completed.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2009-017354-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017354-12.